OBJECTIVES: This study sought to assess the impact of body mass index (BMI) on cardiac phenotypic and clinical course in a multicenter hypertrophic cardiomyopathy (HCM) cohort. BACKGROUND: It is unresolved whether clinical variables promoting left ventricular (LV) hypertrophy in the general population, such as obesity, may influence cardiac phenotypic and clinical course in patients with HCM. METHODS: In 275 adult HCM patients (age 48 ± 14 years; 70% male), we assessed the relation of BMI to LV mass, determined by cardiovascular magnetic resonance (CMR) and heart failure progression. RESULTS: At multivariate analysis, BMI proved independently associated with the magnitude of hypertrophy: pre-obese and obese HCM patients (BMI 25 to 30 kg/m(2) and >30 kg/m(2), respectively) showed a 65% and 310% increased likelihood of an LV mass in the highest quartile (>120 g/m(2)), compared with normal weight patients (BMI <25 kg/m(2); hazard ratio [HR]: 1.65; 95% confidence interval [CI]: 0.73 to 3.74, p = 0.22 and 3.1; 95% CI: 1.42 to 6.86, p = 0.004, respectively). Other features associated with LV mass >120 g/m(2) were LV outflow obstruction (HR: 4.9; 95% CI: 2.4 to 9.8; p < 0.001), systemic hypertension (HR: 2.2; 95% CI: 1.1 to 4.5; p = 0.026), and male sex (HR: 2.1; 95% CI: 0.9 to 4.7; p = 0.083). During a median follow-up of 3.7 years (interquartile range: 2.5 to 5.3), obese patients showed an HR of 3.6 (95% CI: 1.2 to 10.7, p = 0.02) for developing New York Heart Association (NYHA) functional class III to IV symptoms compared to nonobese patients, independent of outflow obstruction. Noticeably, the proportion of patients in NYHA functional class III at the end of follow-up was 13% among obese patients, compared with 6% among those of normal weight (p = 0.03). CONCLUSIONS: In HCM patients, extrinsic factors such as obesity are independently associated with increase in LV mass and may dictate progression of heart failure symptoms.
OBJECTIVES: This study sought to assess the impact of body mass index (BMI) on cardiac phenotypic and clinical course in a multicenter hypertrophic cardiomyopathy (HCM) cohort. BACKGROUND: It is unresolved whether clinical variables promoting left ventricular (LV) hypertrophy in the general population, such as obesity, may influence cardiac phenotypic and clinical course in patients with HCM. METHODS: In 275 adult HCM patients (age 48 ± 14 years; 70% male), we assessed the relation of BMI to LV mass, determined by cardiovascular magnetic resonance (CMR) and heart failure progression. RESULTS: At multivariate analysis, BMI proved independently associated with the magnitude of hypertrophy: pre-obese and obese HCMpatients (BMI 25 to 30 kg/m(2) and >30 kg/m(2), respectively) showed a 65% and 310% increased likelihood of an LV mass in the highest quartile (>120 g/m(2)), compared with normal weight patients (BMI <25 kg/m(2); hazard ratio [HR]: 1.65; 95% confidence interval [CI]: 0.73 to 3.74, p = 0.22 and 3.1; 95% CI: 1.42 to 6.86, p = 0.004, respectively). Other features associated with LV mass >120 g/m(2) were LV outflow obstruction (HR: 4.9; 95% CI: 2.4 to 9.8; p < 0.001), systemic hypertension (HR: 2.2; 95% CI: 1.1 to 4.5; p = 0.026), and male sex (HR: 2.1; 95% CI: 0.9 to 4.7; p = 0.083). During a median follow-up of 3.7 years (interquartile range: 2.5 to 5.3), obesepatients showed an HR of 3.6 (95% CI: 1.2 to 10.7, p = 0.02) for developing New York Heart Association (NYHA) functional class III to IV symptoms compared to nonobese patients, independent of outflow obstruction. Noticeably, the proportion of patients in NYHA functional class III at the end of follow-up was 13% among obesepatients, compared with 6% among those of normal weight (p = 0.03). CONCLUSIONS: In HCM patients, extrinsic factors such as obesity are independently associated with increase in LV mass and may dictate progression of heart failure symptoms.
Keywords:
BMI; CMR; HCM; HR; LGE; LV; LVH; NYHA; New York Heart Association; body mass index; cardiac magnetic resonance; cardiovascular magnetic resonance; hazard ratio; hypertrophic cardiomyopathy; hypertrophy; late gadolinium enhancement; left ventricular; left ventricular hypertrophy; obesity; outcome
Authors: Tomas Konecny; Jeffrey B Geske; Ondrej Ludka; Marek Orban; Peter A Brady; Muaz M Abudiab; Felipe N Albuquerque; Alexander Placek; Tomas Kara; Karine R Sahakyan; Bernard J Gersh; A Jamil Tajik; Thomas G Allison; Steve R Ommen; Virend K Somers Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Marco Canepa; Lars L Sorensen; Iraklis Pozios; Veronica L Dimaano; Hong-Chang Luo; Aurelio C Pinheiro; James B Strait; Claudio Brunelli; M Roselle Abraham; Luigi Ferrucci; Theodore P Abraham Journal: Am J Cardiol Date: 2013-10-15 Impact factor: 2.778
Authors: Carlo Fumagalli; Niccolò Maurizi; Sharlene M Day; Euan A Ashley; Michelle Michels; Steven D Colan; Daniel Jacoby; Niccolò Marchionni; Justin Vincent-Tompkins; Carolyn Y Ho; Iacopo Olivotto Journal: JAMA Cardiol Date: 2020-01-01 Impact factor: 14.676
Authors: Meghann McKane; Jonathan H Soslow; Meng Xu; Benjamin R Saville; James C Slaughter; W Bryan Burnette; Larry W Markham Journal: J Child Neurol Date: 2017-01-13 Impact factor: 1.987